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a b s t r a c t
Background: Women are underrepresented in major atrial fibrillation (AF) trials. In addition, data regard-
ing clinical profile and outcome in young AF patients is limited. Therefore we aimed to investigate the
clinical profile, AF progression rate and cardiovascular outcome between sexes in patients with young-
onset AF.
Methods: A total of 497 patients with AF-onset <60 years of age were included. Data on clinical profile
and cardiovascular outcome were prospectively collected.
Results: Of 497 patients, 125 (25%) patients were women. Women had more often familial AF (34% versus
22%, P = 0.012) and obesity (26% versus 18%, P = 0.03). Men had more often coronary artery disease (11%
versus 5%, P = 0.04), a longer PR interval [163 (148–180) versus 150 (138–167) ms, P < 0.001] and higher
left ventricular mass index [82 (71–96) versus 72 (61–83) g/m2, P < 0.001]. During a median follow-up of
7.0 (2.7–10.0) years AF progression rate was comparable (HR 2.03 for men versus women, 95%CI 0.92–
4.48; P = 0.08), and no difference in cardiovascular events was observed between women and men
(Log rank P-value = 0.07).
Conclusions: In young patients with AF, clinical patient profile is different between the sexes but did not
result in differences in cardiovascular outcome.
 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Atrial fibrillation (AF) is strongly associated with morbidity and
mortality [1]. Most data on AF is obtained from clinical trials, yet
women are often underrepresented [2–4]. Limited data suggest
that women are generally older and have different comorbidities,
i.e. more often hypertension and less often coronary artery disease
[2–4]. Additionally, sex is an independent stroke risk modifier that
increases the risk of AF associated stroke in women. On top of
higher stroke risk, stroke in women with AF have worse long-
term outcome [5–7].
Data regarding underlying diseases in young patients with AF is
rare, and may be different compared to older patients [8]. One
would ideally like to identify underlying comorbidities early on
in order to potentially prevent disease progression [9]. It has been
shown that familial history of AF is often present in young-onset
AF [8]. Whether there are risk factors that specifically affect
women or men in young-onset AF has not yet been reported.
Therefore we aimed to investigate sex-differences in clinical pro-




The protocol of the Phenotyping Young-Onset Atrial Fibrillation
Patients study (YOUNG-AF) has been published previously [10]. In
brief, YOUNG-AF was a partly prospective, partly retrospective,
observational study performed at the University Medical Center
Groningen, The Netherlands. Between August 2012 and December
2013, 500 patients were included. The study was performed in
compliance to the Declaration of Helsinki and the institutional
review board approved the study protocol. All patients provided
written informed consent. At the outpatient clinic patients with
AF onset <60 years, 18 years at time of inclusion were asked to
participate. Patients with an overt triggered AF were excluded
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(i.e. post-operative). A total of 120 patients had first-detected AF,
the remaining 377 patients had recurrent AF. In those patients,
data regarding clinical profile was collected closest to the moment
of the diagnosis of AF (index-visit). Follow-up frequency after the
index-visit was led to the discretion of the treating physician and
all patients received treatment according to the guidelines [11].
Three patients were excluded because of violation of the inclusion
and exclusion criteria.
2.2. Definitions
The majority of definitions have been previously published [10].
Familial history of AF, sudden cardiac death, coronary artery dis-
ease or heart failure was defined as 1 first-degree family member
affected <60 years of age. Atrial fibrillation progression was
defined as development of permanent AF (i.e. sinus rhythm that
cannot be restored or is no longer pursued). The number of comor-
bidities was calculated by awarding a point for hypertension; heart
failure; diabetes mellitus; coronary artery disease; body mass
index >25 kg/m2; kidney dysfunction (estimated glomerular filtra-
tion rate <60 ml/min/1.73 m2); and moderate to severe mitral
valve regurgitation.
2.3. Follow-up
Data from electronic medical records were used to obtain infor-
mation on AF progression and cardiovascular events, including car-
diovascular death, heart failure hospitalization, stroke, systemic
embolism, major bleeding, syncope, life-threatening adverse
effects of AF drugs, sustained ventricular tachycardia, cardiac
arrest and implantation of a pacemaker or implantable cardiac
defibrillator. All cardiovascular events were adjudicated by physi-
cians. Follow-up started at index-visit and was continued until
February 2016 with a maximum of 10 years, or until death.
Follow-up data was available in 488 out of 497 patients (98%). Data
on AF progression was available in 468 (94%) patients with parox-
ysmal or persistent AF at the index visit.
2.4. Statistical analysis
Descriptive statistics of the total population and between sexes
were presented as mean and standard deviation or median
(interquartile range) for continuous variables, depending on nor-
mality. Categorical variables are presented as numbers with per-
centages. AF progression rate differences between sexes were
calculated using univariable Cox proportional hazards regression,
indicated as hazard ratios (HR) with 95% confidence interval (CI).
Yearly event rates were calculated by dividing the number of
follow-up years by the number of events, with censoring post first
event. Differences in event rates and 95% CI were calculated by the
MedCalc incidence rate comparison tool. Differences in patient
characteristics between sexes were evaluated using v2 for categor-
ical data, and Student’s T-test and Mann-Whitney-U for continuous
data, depending on the normality. A P-value <0.05 was considered
significant. Kaplan Meier analysis was performed to illustrate car-
diovascular events during follow-up. Statistical analyses were per-
formed using IBM SPSS Statistics version 23.0 (Armonk, NY, USA)
unless otherwise mentioned.
3. Results
3.1. Clinical patient profile
Out of 497 patients, 125 (25%) were women. Most conventional
risk factors, including age, hypertension, heart failure and diabetes
mellitus, were not different between sexes (Table 1). Women had
more often familial AF and obesity. Men had more often coronary
artery disease, a longer PR interval and higher left ventricular mass
index. As expected, men were taller and heavier. There were no sex
differences in familial history of sudden cardiac death, early-onset
coronary artery disease or heart failure. Thirty patients were diag-
nosed with a cardiomyopathy, which was not different between
sexes [12 (2%) hypertrophic; 17 (3%) dilated; and 1 (<1%)
arrhythmogenic].
3.2. AF progression
AF progression to permanent AF was assessed in 468 patients
with paroxysmal or persistent AF at the index visit [114 (24%)
women]. Fifty-six patients (12%) had AF progression. Without cor-
recting for underlying diseases, there was a trend towards more AF
progression in men compared to women (14% in men, 7% in
women; HR 2.02, 95%CI 0.92–4.48, P = 0.08). There were no differ-
ences in class I or III antiarrhythmic drug use during follow up
between sexes [114 (31%) in men versus 42 (35%) in women,
P = 0.500], nor in pulmonary vein isolations performed during
follow-up [150 (41%) in men versus 51 (42%) in women,
P = 0.832]. Corrected for antiarrhythmic drug use and pulmonary
vein isolation performed during follow-up, progression rate
remained similar between sexes (HR 1.93, 95% CI 0.88–4.28,
P = 0.10).
3.3. Cardiovascular outcome
During follow-up of 7.0 [2.7–10.0; in men 7.6 (2.9–10.0) versus
6.4 (2.5–10.0) in women, P = 0.160] years, 66 cardiovascular events
occurred (yearly event rate 2.24%, 95%CI 1.73–2.85%). No differ-
ence between sexes in the composite of cardiovascular events
was observed [yearly event rate 2.76% (95%CI 1.71–4.22) in
women; 2.01% (95%CI 1.46–2.70) in men, P = 0.07; Fig. 1]. Cor-
rected for treatment during follow up, including the use of antiar-
rhythmic drugs and pulmonary vein isolation, the results remained
(HR 1.91, 95% 0.86–4.24, P = 0.11). Occurrence of ventricular tachy-
cardia was more frequent in women [yearly event rate 0.57% (95%
CI 0.18–1.32%) versus 0.12% (95%CI 0.03–0.37%), P = 0.02]. Two out
of 5 women used antiarrhythmic drugs at the time of VT. Also, a
trend towards more pacemaker implantations in women was
observed [1.34% (95%CI 0.67–2.39) versus 0.65% (95%CI 0.36–
1.07); P = 0.06]. Sick sinus syndrome (50%), atrioventricular node
conduction disorders (19%) and therapy resistant AF (31%) were
causes for pacemaker implantation.
4. Discussion
We studied sex differences in clinical profile and cardiovascular
outcome in young-onset AF patients. Women with young-onset AF
had more often familial AF and obesity, whereas men had more
coronary artery disease, a longer PR interval and higher left ven-
tricular mass. We observed no difference in AF progression rate
nor in cardiovascular outcome between sexes during 7-year
follow-up.
In our prospective cohort, one out of four patients were women.
AF is a rare disease in the young, and the probable misnomer ‘lone
AF’ remains a diagnosis of exclusion [8–10]. Careful evaluation for
cardiovascular risk factors should therefore be performed. Women
had more often a family history of AF. Familial AF has been
reported in 5–30% of patients [8]. Besides the genetic risk of AF
itself, genetic susceptibility to other cardiovascular diseases may
also play a role in the high rate of familial AF in young-onset AF
[12]. Yet, many risk factors may remain subclinical and therefore
2 E.G. Marcos et al. / IJC Heart & Vasculature 25 (2019) 100429
Downloaded for Anonymous User (n/a) at University of Groningen from ClinicalKey.com by Elsevier on February 26, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
untreated for years. In fact, AF might be the first clinical presenta-
tion of an underlying cardiomyopathy. The number of cardiomy-
opathies was, however, still low in our population. Of interest is
the relatively high number of reported familial sudden cardiac
death, which may be due to underlying cardiomyopathies or other
untreated cardiovascular (genetic) diseases.
Identification and treating risk factors and comorbidities is
important in AF treatment, and preventing progression of atrial
remodeling [9,13]. We observed no difference in AF progression
rate between sexes. AF progression is a complex process mainly
driven by comorbidity and ageing related atrial remodeling [14].
The equal number of comorbidities and similar age between men
and women in our cohort may have contributed in finding similar
progression rate.
Obesity, a modifiable risk factor for AF, was observed more
often in women [15,16]. Obesity has been associated with a pro-
thrombotic state [17,18]. On top of that, obesity-related cardiac
remodeling, including epicardial adipose tissue infiltration, inflam-
mation and fibrosis, enhances AF substrate formation, also causing
AF to progress and sustain [18]. The higher incidence of coronary
artery disease in men is well known. It should therefore always
be considered causal factor associated with AF – especially in
men. Even in patients diagnosed with idiopathic AF, half showed
coronary artery disease as assessed by noninvasive imaging [19].
PR interval and left ventricular mass were both higher in men com-
pared to women. Both have previously been associated with car-
diovascular outcome in patients with AF [10].
Table 1








Age at index-visit (years) 49 ± 9 51 ± 8 49 ± 9 0.057
Age at AF-onset (years) 46 ± 9 47 ± 9 46 ± 10 0.128
Type of AF 0.249
Paroxysmal 337 (68%) 89 (71%) 248 (67%)
Persistent 140 (28%) 29 (23%) 111 (30%)
Permanent 20 (4%) 7 (6%) 13 (4%)
Heart failure 53 (11%) 10 (8%) 43 (12%) 0.317
Cardiomyopathy 30 (6%) 5 (4%) 25 (7%) 0.269
Hypertension 218 (44%) 52 (42%) 166 (45%) 0.603
Diabetes mellitus 25 (5%) 7 (6%) 18 (5%) 0.813
Coronary artery disease 47 (10%) 6 (5%) 41 (11%) 0.040
Peripheral artery disease 9 (2%) 2 (2%) 7 (2%) 0.838
Stroke or transient ischemic attack 30 (6%) 8 (6%) 22 (6%) 0.844
COPD 19 (4%) 7 (6%) 12 (3%) 0.279
Family history
Familial AF 124 (25%) 42 (34%) 82 (22%) 0.012
Familial sudden cardiac death 48 (10%) 14 (11%) 34 (9%) 0.520
Familial coronary artery disease 109 (22%) 31 (25%) 78 (21%) 0.369
Familial heart failure 25 (5%) 7 (5%) 18 (5%) 1.000
CHA2DS2VASc score 1 (0–2) 2 (1–2) 1 (0–1) <0.001
Number of comorbidities 1.3 ± 1.1 1.3 ± 1.1 1.4 ± 1.1 0.328
EHRA symptom class (n = 460) 0.508
I 46 (10%) 12 (10%) 34 (10%)
II 337 (73%) 82 (69%) 255 (75%)
III 73 (16%) 22 (18%) 51 (15%)
IV 4 (<1%) 2 (2%) 2 (<1%)
Height (cm) 182 ± 10 171 ± 7 185 ± 8 <0.001
Weight (kg) 92 ± 17 83 ± 20 94 ± 15 <0.001
BMI (kg/m2) 27 (24–30) 28 (23–32) 27 (25–30) 0.446
Obesity (BMI > 30) 98 (20%) 33 (26%) 65 (18%) 0.030
PR interval (ms) 160 (144–176) 150 (138–167) 163 (148–180) <0.001
Class I antiarrhytmic drug use 68 (14%) 22 (18%) 46 (13%) 0.131
Class III antiarrhytmic drug use 88 (18%) 20 (17%) 68 (18%) 0.684
Echocardiography
Moderate or severe valve disease 39 (8%) 8 (6%) 31 (8%) 0.568
Left ventricular mass index (g/m2) 80 (69–93) 72 (61–83) 82 (71–96) <0.001
LA volume index (mL/m2) 31 (25–31) 19 (23–32) 26 (21–32) 0.261
LVEF (%) 60 (55–60) 60 (55–60) 60 (55–60) 0.673
Data is expressed as mean and standard deviation, median (IQR) or numbers (%).
Abbreviations: AF = atrial fibrillation; BMI = body mass index; EHRA = European Heart Rhythm Association; LA = left atrial; LVEF = left ventricular ejection fraction. The
number of comorbidities was calculated by awarding points for a history of hypertension, heart failure, diabetes, coronary artery disease, body mass index >25 kg/m2, kidney
dysfunction and moderate or severe mitral valve disease.
Fig. 1. Kaplan Meier curve illustrating the cumulative incidence of cardiovascular
events during follow-up.
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Women with AF may have worse cardiovascular outcome, yet
women tend to be older and have more comorbidities [3]. We
found no sex difference in cardiovascular outcome in our young-
onset AF cohort, which can be partially accounted to the relatively
low number of events in general due to the young age. Yet, a trend
was observed towards a higher event rate in women, especially
after 3 years of follow-up, which could be related to differences
in underlying disease in men and women.
5. Limitations
Strengths of present study include a well-characterized cohort
and unique dataset of young-onset AF patients. Whether the asso-
ciations that were found reflect cause-effect relationships cannot
be concluded from our data, which may be considered a limitation,
as well as the limited number of cardiovascular events. A time-to-
event analysis was performed for AF progression to permanent AF
without structured rhythm monitoring during follow-up, limiting
its accuracy. Because of this, we were also unable to determine
progression from paroxysmal to persistent AF. Furthermore we
did not have follow-up data on blood pressure and weight, limiting
our knowledge on risk factor management in our population.
6. Conclusion
The clinical profile between men and women with young-onset
AF is different. We observed no differences in AF progression rate
between men and women, nor differences in cardiovascular
outcome.
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